Trial reportJournal of pediatric gastroenterology and nutrition2010
A randomized controlled trial of growth hormone in active pediatric Crohn disease.
Trial report in Journal of pediatric gastroenterology and nutrition, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 51 citations in OpenAlex.
- A Theoretical Link Between the GH/IGF-1 Axis and Cytokine Family in Children: Current Knowledge and Future Perspectives.Children (Basel, Switzerland) · 2025Review
- A Masking Effect: A Case of Initial Presentation of Ulcerative Colitis After Discontinuing Growth Hormone Therapy.Crohn's & colitis 360 · 2023Article
- Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma.Microbiology spectrum · 2022Article
- Growth Delay in Inflammatory Bowel Diseases: Significance, Causes, and Management.Digestive diseases and sciences · 2021Review
- Intestinal CaWorld journal of gastroenterology · 2020Review
- Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis.International journal of molecular sciences · 2017Article
- Growth Hormone Resistance-Special Focus on Inflammatory Bowel Disease.International journal of molecular sciences · 2017Review
- Interaction of obesity and inflammatory bowel disease.World journal of gastroenterology · 2016Review
- Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease.Pilot and feasibility studies · 2016Article
- Endocrine therapy for growth retardation in paediatric inflammatory bowel disease.Paediatric drugs · 2014Review
- Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn's disease: despite temporal changes in disease severity, the need for monitoring remains.The Journal of pediatrics · 2013Review
- Article
- The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.Seminars in pediatric surgery · 2013Review
- Use of ghrelin as a treatment for inflammatory bowel disease: mechanistic considerations.International journal of peptides · 2011Article
- Characterization of an intestine-specific GH receptor knockout (IntGHRKO) mouse.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesGrowth hormone (GH) may reduce symptoms and improve growth in Crohn disease (CD). The effect on mucosal inflammation is not known. We hypothesized that GH would improve both clinical and mucosal disease activity and stimulate linear growth in pediatric CD. PATIENTS AND
methodsTwenty patients ages 7 to 18 receiving corticosteroids (CTX) for active CD were randomized to begin GH, 0.075 mg x kg(-1) x day(-1) (group A), or continue CTX alone (group B). Clinical and endoscopic disease activities were assessed after 12 weeks. Group B began GH at 12 weeks, and clinical disease activity was assessed at 24 weeks. Subjects who experienced a clinical response after 12 weeks of GH therapy continued treatment for an additional 52 weeks, and linear growth was assessed.
resultsSixty-five percent of patients receiving GH achieved clinical remission, compared with 20% treated with CTX alone (P = 0.03). Although endoscopic disease activity trended toward an improvement at week 12 in group A, this did not differ between the groups. Sixty-one percent of week 12 GH responders maintained their clinical response through week 64. Mean (95th confidence interval) height z score on GH increased from -1.1 (-1.6, -0.6) to -0.4 (-1, 0.2), P = 0.004 during this 52-week extension phase. GH was well tolerated with no unexpected safety signals.
conclusionsThe addition of GH to CTX therapy did not induce a reduction in mucosal inflammation, relative to CTX alone. However, GH was safe and effective as an adjunct to CTX for treatment of clinical disease activity and growth failure in pediatric CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.